Lyra Therapeutics reported a net margin of -12,428.57% for the quarter ended Dec 2025. These financial ratios cover 24 quarters of results from Mar 2020 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||
| EBT Margin | -78,964.29% | -5,024.72% | -2,545.09% | -2,736.38% | -4,113.09% | -129,290.91% | -3,961.22% | -3,407.42% | -2,874.08% | -10,369.18% | -4,217.67% | -8,046.66% | -6,085.13% | -5,250.24% | -4,668.31% | -4,062.84% | -23,924.00% | -99,271.43% | ||||||
| EBIT Margin | -79,150.00% | -5,032.47% | -2,548.08% | -2,742.86% | -4,129.81% | -137,772.73% | -4,222.68% | -3,603.28% | -3,093.20% | -11,285.62% | -4,421.80% | -8,189.63% | -6,380.51% | -5,458.37% | -4,831.15% | -4,822.95% | -24,948.00% | -101,685.71% | ||||||
| EBITDA Margin | -79,150.00% | -5,032.47% | -2,548.08% | -2,742.86% | -4,129.81% | -137,772.73% | -4,222.68% | -3,603.28% | -3,093.20% | -11,285.62% | -4,421.80% | -8,189.63% | -6,380.51% | -5,458.37% | -4,831.15% | -4,822.95% | -24,948.00% | -101,685.71% | ||||||
| Operating Margin | -79,150.00% | -5,032.47% | -2,548.08% | -2,742.86% | -4,129.81% | -137,772.73% | -4,222.68% | -3,603.28% | -3,093.20% | -11,285.62% | -4,421.80% | -8,189.63% | -6,380.51% | -5,458.37% | -4,831.15% | -4,822.95% | -24,948.00% | -101,685.71% | ||||||
| Net Margin | -78,964.29% | -5,024.72% | -2,545.09% | -2,736.38% | -4,113.09% | -129,290.91% | -3,964.63% | -3,410.04% | -2,877.02% | -10,380.82% | -4,220.30% | -8,048.66% | -6,088.72% | 4,150.24% | -4,670.49% | -4,063.93% | -23,936.00% | -12,428.57% | ||||||
| FCF Margin | -77,364.29% | -4,568.27% | -2,563.68% | -1,616.00% | -3,029.25% | -110,836.36% | -3,876.83% | -3,133.84% | -2,620.96% | -13,592.47% | -4,624.81% | -3,374.08% | -8,345.64% | -5,403.83% | -4,831.69% | -3,601.09% | -29,632.00% | -87,357.14% | ||||||
| Efficiency | ||||||||||||||||||||||||
| Assets AverageAssets Avg. | 76.87M | 74.62M | 72.05M | 61.31M | 51.11M | 88.69M | 124.75M | 114.72M | 101.92M | 109.77M | 123.12M | 131.59M | 142.06M | 118.05M | 86.67M | 72.55M | 61.33M | 54.44M | 48.14M | 39.91M | ||||
| Asset Utilization RatioAsset Util. | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |||||||
| Return Ratios | ||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -79,150.00% | -5,032.47% | -2,548.08% | -2,742.86% | -4,129.81% | -137,772.73% | -4,222.68% | -3,603.28% | -3,093.20% | -11,285.62% | -4,421.80% | -8,189.63% | -6,380.51% | -5,458.37% | -4,831.15% | -4,822.95% | -24,948.00% | -101,685.71% | ||||||
| Return on Capital Employed [ROCE]ROCE | -35.48% | -47.02% | -68.23% | -101.27% | -163.72% | -65.37% | -49.30% | -56.17% | -70.30% | -66.69% | -63.33% | -59.93% | -59.45% | -107.11% | -141.42% | -160.79% | -163.79% | -95.92% | -91.34% | -102.09% | ||||
| Return on Assets [ROA]ROA | -33.43% | -43.14% | -51.24% | -70.97% | -93.18% | -57.45% | -43.82% | -48.18% | -58.49% | -55.44% | -50.15% | -47.63% | -48.48% | -85.88% | -112.63% | -101.70% | -97.63% | -35.23% | -27.61% | -57.23% |